Post-Covid Condition Cohort: Evolution of Symptomatology, Patient Profile and Associated Prognostic Factors (SYNPOCov)

Post-Covid Condition Monitoring Cohort: Evaluation of the Evolution of Symptomatology, Patient Profile and Associated Prognostic Factors

The aim of our cohort is to collect prospectively, in a standardized and exhaustive manner, the health data of patients referred to the CAPCoV, our holistic referal post covid clinics for post-covid condition in order to be able to identify typical profiles of patients suffering from post covid syndrome and to follow the evolution of their disease over time.

Study Overview

• Status: Recruiting
• Conditions: Post-Acute COVID19 Syndrome; Long COVID; Post-Acute COVID-19

• Study Type: Observational
• Enrollment (Anticipated): 500

Contacts and Locations

• Study Contact: Name: Francois GOEHRINGER, MD; Phone Number: +33383154097; Email: francois.goehringer@chru-nancy.fr

Study Locations

• France
  • Grand Est
    • Vandoeuvre les nancy, Grand Est, France, 54511
      • Recruiting
      • Nancy University Hospital
      • Contact: Francois GOEHRINGER, MD; Phone Number: +33383154097; Email: francois.goehringer@chru-nancy.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

outpatients treated in the Nancy University Hospital Long Covid Support and Care Center for post-Covid condition according to WHO definition

Description

Inclusion Criteria:

• outpatients treated in the Nancy University Hospital Long Covid Support and Care Center for post-Covid condition according to WHO definition

Exclusion Criteria:

• patient opposing the processing for research purposes of their data collected in routine care for their care

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Symptoms	Symptoms collected in a standardized manner during consultations, their persistence over time, their evolution (improvement, stagnation, worsening) and their severity (mild, moderate, severe)	every 6 months up to 3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Medical history		baseline
fatigue	Chalder scale: range 0 to 33, >22/33 classified severe	every 6 months up to 3 years
Dyspnea	mMRC	every 6 months up to 3 years
Cognitive impairement	Montréal Cognitive Assessment : range 0 to 30, <26/30 classified pathologic	every 6 months up to 3 years
inappropriate hyperventilation syndrome	Nijmegen score: range 0 to 64, >23/34 classified "possible inapropriate hyperventilation" syndrome"	every 6 months up to 3 years
additional examinations	Biology, imaging	every 6 months up to 3 years

Collaborators and Investigators

• Sponsor: Central Hospital, Nancy, France
• Investigators: Principal Investigator: Francois GOEHRINGER, MD, Infectious Diseases Department, Nancy University Hospital,F-54000 Nancy, France.

Study record dates

Study Major Dates

• Study Start (Actual): January 7, 2022
• Primary Completion (Anticipated): December 1, 2025
• Study Completion (Anticipated): June 1, 2026

Study Registration Dates

• First Submitted: October 20, 2022
• First Submitted That Met QC Criteria: November 8, 2022
• First Posted (Actual): November 9, 2022

Study Record Updates

• Last Update Posted (Actual): November 9, 2022
• Last Update Submitted That Met QC Criteria: November 8, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: 2022PI148

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No